Arthritis drug takes on HIV's last hiding spot: the brain

NCT ID NCT05452564

First seen Mar 24, 2026 · Last updated May 15, 2026 · Updated 4 times

Summary

This study tests whether baricitinib, an FDA-approved arthritis pill, can lower the amount of HIV hiding in the brain. Even when standard HIV therapy keeps the virus low in the blood, it can persist in the central nervous system. About 95 adults with well-controlled HIV will receive baricitinib or a placebo for 24 weeks. Researchers will use spinal taps, blood tests, and thinking assessments to measure changes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Emory University Hospital

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Grady Memorial Hospital

    RECRUITING

    Atlanta, Georgia, 30303, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.